Guided Therapeutics Inc
Guided Therapeutics, Inc., a medical technology company, develops medical devices. It focuses on the marketing and sale of LuViva, an advanced cervical scan non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. Th… Read more
Guided Therapeutics Inc (GTHP) - Net Assets
Latest net assets as of September 2025: $-5.65 Million USD
Based on the latest financial reports, Guided Therapeutics Inc (GTHP) has net assets worth $-5.65 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($903.00K) and total liabilities ($6.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.65 Million |
| % of Total Assets | -625.25% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Guided Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Guided Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guided Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Guided Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-4.89 Million | -28.46% |
| 2023-12-31 | $-3.81 Million | -32.02% |
| 2022-12-31 | $-2.88 Million | +47.05% |
| 2021-12-31 | $-5.45 Million | +49.84% |
| 2020-12-31 | $-10.86 Million | +35.90% |
| 2019-12-31 | $-16.93 Million | -7.02% |
| 2018-12-31 | $-15.82 Million | +18.44% |
| 2017-12-31 | $-19.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guided Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1517600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $148.82 Million | % |
| Total Equity | $-4.89 Million | 100.00% |
Guided Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Guided Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sin-Kung Logistics Berhad
KLSE:0305
|
$2.17 Million |
|
Ambertech Ltd
AU:AMO
|
$2.18 Million |
|
LCC Infotech Limited
NSE:LCCINFOTEC
|
$2.18 Million |
|
ARIP Public Company Limited
BK:ARIP
|
$2.18 Million |
|
C29 Metals Ltd
AU:C29
|
$2.17 Million |
|
Nova Organic PCL
BK:NV
|
$2.17 Million |
|
ROYAL GOLD (RG3.SG)
STU:RG3
|
$2.17 Million |
|
CannBioRx Life Sciences Corp
NASDAQ:ATNFW
|
$2.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guided Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,806,000 to -4,889,000, a change of -1,083,000.
- Net loss of 2,417,000 reduced equity.
- Other factors increased equity by 1,334,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.42 Million | -49.44% |
| Other Changes | $1.33 Million | +27.29% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Guided Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-313.17 | $0.08 | x |
| 2018-12-31 | $-5.93 | $0.08 | x |
| 2019-12-31 | $-5.10 | $0.08 | x |
| 2020-12-31 | $-0.83 | $0.08 | x |
| 2021-12-31 | $-0.40 | $0.08 | x |
| 2022-12-31 | $-0.06 | $0.08 | x |
| 2023-12-31 | $-0.07 | $0.08 | x |
| 2024-12-31 | $-0.08 | $0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guided Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -34528.57%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -4383.61% | 0.50x | 0.00x | $-8.76 Million |
| 2018 | 0.00% | 1782.46% | 0.24x | 0.00x | $2.60 Million |
| 2019 | 0.00% | -5336.11% | 0.03x | 0.00x | $-227.50K |
| 2020 | 0.00% | -273.53% | 0.08x | 0.00x | $806.50K |
| 2021 | 0.00% | -2555.56% | 0.04x | 0.00x | $-1.53 Million |
| 2022 | 0.00% | -33392.31% | 0.00x | 0.00x | $-4.05 Million |
| 2023 | 0.00% | -3560.20% | 0.06x | 0.00x | $-3.11 Million |
| 2024 | 0.00% | -34528.57% | 0.01x | 0.00x | $-1.93 Million |
Industry Comparison
This section compares Guided Therapeutics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guided Therapeutics Inc (GTHP) | $-5.65 Million | 0.00% | N/A | $2.17 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |